Summary of key recommendations

Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults

Class I

"1.Clinical ASCVD Age 75 y and no safety concerns: High-intensity statin (Level of Evidence: A)" Age >75 y or safety concerns: Moderate-intensity statin(Level of Evidence: A)"

"2.Primary prevention – Primary LDL-C ‡190 mg/dL Rule out secondary causes of hyperlipidemia Age !21 y: High-intensity statin(Level of Evidence: B)"

"3.Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL Moderate-intensity statin(Level of Evidence: A)"

"4. Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equationsy in those NOT receiving a statin; estimate risk every 4–6 y(Level of Evidence: B)"

Class III (Harm)

"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"

"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

Class III (No Benefit)

"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"

"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

Class IIa

"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"

"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

Class IIb

"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"

"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

References

Template:WikiDoc Sources CME Category::Cardiology